TY - JOUR
T1 - Chronic myeloid leukemia
T2 - Sequencing of TKI therapies
AU - Cortes, Jorge
AU - Kantarjian, Hagop
N1 - Funding Information:
Conflict-of-interest disclosure: J.C. has received research funding from Novartis, Pfizer, TEVA Pharmaceuticals Industries, Arog Pharmaceuticals, Astellas Pharma, Ambit Biosciences, Bristol-Myers Squibb, and ARIAD Pharmaceuticals and has consulted for Novartis, Pfizer, Bristol-Myers Squibb, and ARIAD Pharmaceuticals. H.K. declares no competing financial interests.
PY - 2016
Y1 - 2016
N2 - Multiple tyrosine kinase inhibitors (TKIs) are available for managing patients with chronic myeloid leukemia. Although most patients have a favorable outcome with their initial therapy, whether imatinib or a second-generation TKI was used, some will require subsequent use of one or more different TKIs. Such sequencing might be indicated in a reactive way (ie, for patients who have experienced resistance or intolerance to their initial therapy) or in a proactive way (ie, for patients with a somewhat favorable outcome who have not reached an "optimal" outcome). Sequencing of TKIs has become standard practice, and the proper use of sequenced TKIs is likely to optimize outcomes and resource utilization.
AB - Multiple tyrosine kinase inhibitors (TKIs) are available for managing patients with chronic myeloid leukemia. Although most patients have a favorable outcome with their initial therapy, whether imatinib or a second-generation TKI was used, some will require subsequent use of one or more different TKIs. Such sequencing might be indicated in a reactive way (ie, for patients who have experienced resistance or intolerance to their initial therapy) or in a proactive way (ie, for patients with a somewhat favorable outcome who have not reached an "optimal" outcome). Sequencing of TKIs has become standard practice, and the proper use of sequenced TKIs is likely to optimize outcomes and resource utilization.
UR - http://www.scopus.com/inward/record.url?scp=85020375225&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020375225&partnerID=8YFLogxK
U2 - 10.1182/asheducation-2016.1.164
DO - 10.1182/asheducation-2016.1.164
M3 - Article
C2 - 27913476
AN - SCOPUS:85020375225
SN - 1520-4391
VL - 2016
SP - 164
EP - 169
JO - Hematology
JF - Hematology
IS - 1
ER -